Edwards Lifesciences (NYSE:EW) Trading Up 0.7%

Edwards Lifesciences Co. (NYSE:EWGet Free Report) shares were up 0.7% during mid-day trading on Wednesday . The stock traded as high as $91.94 and last traded at $90.95. Approximately 616,629 shares changed hands during trading, a decline of 83% from the average daily volume of 3,560,149 shares. The stock had previously closed at $90.34.

Analyst Ratings Changes

Several equities analysts have recently issued reports on EW shares. Evercore ISI cut their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. Citigroup raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the company from $98.00 to $105.00 in a research note on Wednesday. Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the company from $86.00 to $103.00 in a research note on Tuesday, May 14th. Mizuho raised their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, Stifel Nicolaus increased their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.31.

Read Our Latest Stock Analysis on EW

Edwards Lifesciences Stock Performance

The company has a market capitalization of $53.02 billion, a price-to-earnings ratio of 37.88, a PEG ratio of 3.30 and a beta of 1.10. The stock has a 50-day moving average price of $89.77 and a 200-day moving average price of $81.38. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $85.59, for a total value of $620,955.45. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,632,543.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $85.59, for a total value of $620,955.45. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,632,543.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was bought at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 180,707 shares of company stock valued at $16,034,814. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at $28,000. Riverview Trust Co bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $34,000. DSM Capital Partners LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $34,000. Finally, Rise Advisors LLC grew its position in shares of Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after buying an additional 265 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.